Gravita Diagnostyka I Leczenie Nieplodnosci

Research site

Poland Ul. Gen. Karola Kniaziewicza 20a, 91-347 Lodz, Poland

Human papilloma virus immunisation · Meningococcal immunisation · Pneumococcal immunisation
Adults and children

About Specializations

Gravita Diagnostyka I Leczenie Nieplodnosci in Lodz, Poland specialises in clinical trials of conditions such as Human papilloma virus immunisation, Meningococcal immunisation, Pneumococcal immunisation, Pneumococcal infection, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System Processes

At Gravita Diagnostyka I Leczenie Nieplodności, researchers are investigating how the body’s immune defenses can be harnessed to prevent serious viral diseases. Current work includes evaluating the protective effect of a monoclonal antibody against respiratory syncytial virus (RSV) in young children, and studying the immune response generated by a 9‑valent human papillomavirus (HPV) vaccine administered with varied dosing schedules to adolescents. The overarching goal is to confirm safety, tolerability, and strong immunogenicity of these preventive strategies.

Assessment of RSV prophylaxis in infants
Optimization of HPV vaccine dosing for pre‑teens and teens
Comprehensive safety monitoring of investigational vaccines

The Łódź‑based site has launched two clinical studies, involving three investigators, to advance vaccine science and improve public health outcomes.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Gen. Karola Kniaziewicza 20a91-347 LodzPoland

Open in maps ↗

Recruiting now: no trials
Conditions studied: 5

More sites in Lodz Poland

All trials

Ongoing trials

Clinical trials registered at this site – none is enrolling right now.

Quick filters

5 clinical trials

Pneumococcal immunisation

Not recruiting

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

InvestigationalNo placebo

Study on the Safety and Immune Response of a 21-Valent Pneumococcal Vaccine in Healthy Infants, Toddlers, Children, and Adolescents

InvestigationalNo placebo

Poland

Participants:0–17 years · Healthy volunteers
Substances:Pneumococcal polysaccharide serotype 1
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Meningococcal immunisation

Not recruiting

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo

Safety and immunogenicity study of Pentavalent Meningococcal ABCYW vaccine (MenPenta SD and MenPenta fHD) compared to licensed meningococcal vaccines in infants, toddlers and children

Registered drugNo placebo

Poland

Participants:0–17 years · Healthy volunteers
Substances:Diphtheria toxoid
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Human papilloma virus immunisation

Not recruiting

Study on the Safety and Immune Response of 9vHPV Vaccine in Preventing HPV in Boys and Girls Aged 9-14 Compared to Young Women Aged 16-26

Registered drugNo placebo

Study on the Safety and Immune Response of 9vHPV Vaccine in Preventing HPV in Boys and Girls Aged 9-14 Compared to Young Women Aged 16-26

Registered drugNo placebo

Poland

Participants:0–17 years · 18–64 years · Healthy volunteers
Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Respiratory syncytial virus infection

Not recruiting

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug

Poland

Participants:0–17 years · Healthy volunteers
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Pneumococcal infection

Not recruiting

Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

Registered drugNo placebo

Study on the Safety and Immune Response of V116 Vaccine in Children and Adolescents at Higher Risk for Pneumococcal Disease

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:ABC-15A-116
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites